Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer

Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer is a phase 2, interventional study registered as NCT06204094 by Jinhua Central Hospital, with a registry enrolment figure of 37 participants, started 2024-02-05 and due to reach its primary completion in 2027-09-01. Interventions recorded: node-sparing short-course radiotherapy; Sintilimab; Capecitabine; Oxaliplatin; TME surgery; watch and wait. Conditions listed: Locally Advanced Rectal Cancer. Primary outcome: Complete response. Colorectal eligibility wording from the registry: "* Patients diagnosed with low rectal cancer within 10 cm from the lower edge of the tumor to the anal verge by pelvic MRI and anorectoscopy, the clinical stage is cT2N+M0/cT3-4N0/+M0, the lymph nodes are limited to the mesorectum". Sites: China. No results are recorded here; the registry entry is the source.